Lyphe Group is the UK’s medical cannabis pioneer.

Our vertical operations span product manufacturing, clinical care, pharmacy dispensing and doctor education. Our direct-to-patient and technology-led approach has quickly established us as the market’s largest player, with a 30% share of all patients. We have also recently entered the Australian market, where we intend to replicate our model of success.

Lyphe Group milestones

Feb 2023

Lyphe Group secures growth capital to focus on core UK and Australian markets

Dec 2022

TMCC changes its name to Lyphe Clinic

Aug 2022

Lyphe Australia is launched

Dec 2021

Lyphe become product provider into Europe’s largest RWD registry, Project Twenty21

Jan 2021

Dispensary Green passes milestone of 20,000 units dispensed

Dec 2020

TMCC passes 1,500 unique patients

Nov 2020

NOIDECS medical cannabis range launches into market

Sep 2020

TMCC completes first 1,000 medical cannabis consultations

Aug 2020

Dispensary Green passes milestone of 5,000 units dispensed

May 2020

Close Series A round

Mar 2020

Full telemedicine activation for all The Medical Cannabis Clinics patients

Feb 2020

Astral Health coordinates Israel's first export into the UK

Jan 2020

Open 7 clinic locations across the UK

Dec 2019

CQC granted license for The Medical Cannabis Clinics to open

Oct 2019

Reporters join us on our trip to pick up medication in Holland in a world first